<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230425057992N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-05-16</date_registration>
      <primary_sponsor>Islamic Azad University</primary_sponsor>
      <public_title>Comparison of the effectiveness of ketorolac and diclofenac on reducing pain after surgery</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effectiveness of two combined drug regimens of venous ketorolac and diclofenac suppository in comparison with venous ketorolac alone on reducing pain after abdominal surgery under general anesthesia</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>44</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/69947</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: This study requires 44 patients to be divided into two groups and 22 patients will be placed in each group. For this purpose, the table of random numbers has been used as follows:
In the table of random numbers, a number is chosen randomly with the eyes closed and by shaking the tip of the pen. Then this number is the starting point, and from this number numbers are recorded from the bottom to the top and assigned to different groups. It should be noted that the selected numbers must be two digits and smaller equal to 44.Then the first 22 numbers that were selected are assigned to group A and the next 22 numbers to group B. On the other hand, the patients undergoing surgery are numbered from 1 to 44 from the beginning of the sampling process, and according to the numbers assigned to them, they are in the subgroup A and B are placed. For group A, intravenous ketorolac drug regimen is used along with diclofenac suppositories, and for group B, intravenous ketorolac drug regimen is used alone, Blinding description: The meaning of double-blind is that neither the surgeon nor the patients will know about the randomization method and treatment protocol taken into consideration.</study_design>
      <phase>2</phase>
      <hc_freetext>Pain reduction after abdominal surgery with general anesthesia.</hc_freetext>
      <i_freetext>Intervention 1: intervention group: In this double-blind randomized clinical trial study, patients undergoing elective abdominal surgery with general anesthesia who are in anesthesia class 1 and 2 were interviewed before surgery and background information including gender, age, clinical and medication records were obtained from them. The question is recorded in the study checklist. After complete preparation, placement of intravenous line, monitoring and receiving oxygen for 3 to 5 minutes with premedication of midazolam 2 mg and fentanyl 2 cc and sodium thiopental 5 mg/kg and atracurium 0.5 mg/kg under anesthesia induction. They are placed and then anesthesia is administered with N2O gas and isoflurane oxygen and repetition of fentanyl and atracurium. At the end of the operation and randomly using a random table of numbers, the patients are evaluated in two groups. The first group receives diclofenac suppositories (100 mg each) and Ketorolac ampoules (15 mg) in the form of infusion. Patients will not know about the randomization method and the considered treatment protocol. Pain intensity is measured during the first 6 hours of recovery and the first 12 hours after the operation. In the group with moderate and severe pain, 10 and 20 mg of pethidine is injected, and the consumption of the two groups is compared. Intervention 2: intervention group: In this double-blind randomized clinical trial study, patients undergoing elective abdominal surgery with general anesthesia who are in anesthesia class 1 and 2 were interviewed before surgery and background information including gender, age, clinical and medication records were obtained from them. The question is recorded in the study checklist. After complete preparation, placement of intravenous line, monitoring and receiving oxygen for 3 to 5 minutes with premedication of midazolam 2 mg and fentanyl 2 cc and sodium thiopental 5 mg/kg and atracurium 0.5 mg/kg under anesthesia induction. They are placed and then anesthesia is administered with N2O gas and isoflurane oxygen and repetition of fentanyl and atracurium.At the end of the operation and randomly using a random table of numbers, the patients are evaluated in two groups. The second group receives only Ketorolak ampoules.Patients will not know about the randomization method and the considered treatment protocol. Pain intensity is measured during the first 6 hours of recovery and the first 12 hours after the operation. In the group with moderate and severe pain, 10 and 20 mg of pethidine is injected, and the consumption of the two groups is compared.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Seyede zahra Seyf</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 1, East Payambar Ave, Abazar Blvd, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1473673341</zip>
        <telephone>+98 21 4496 5783</telephone>
        <email>zahra.seyf7596@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyede zahra Seyf</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 1, East Payambar Ave, Abazar Blvd, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1473673341</zip>
        <telephone>+98 21 4496 5783</telephone>
        <email>zahra.seyf7596@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age over 18 years, undergoing all kinds of elective surgeries of the abdominal area under general anesthesia, anesthesia class one and two</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1- Existence of any disease limiting the use of NSAID (patients with gastrointestinal, liver, kidney disorders)
2- Incidence of surgery and anesthesia complications</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>intervention group: In this double-blind randomized clinical trial study, patients undergoing elective abdominal surgery with general anesthesia who are in anesthesia class 1 and 2 were interviewed before surgery and background information including gender, age, clinical and medication records were obtained from them. The question is recorded in the study checklist. After complete preparation, placement of intravenous line, monitoring and receiving oxygen for 3 to 5 minutes with premedication of midazolam 2 mg and fentanyl 2 cc and sodium thiopental 5 mg/kg and atracurium 0.5 mg/kg under anesthesia induction. They are placed and then anesthesia is administered with N2O gas and isoflurane oxygen and repetition of fentanyl and atracurium. At the end of the operation and randomly using a random table of numbers, the patients are evaluated in two groups. The first group receives diclofenac suppositories (100 mg each) and Ketorolac ampoules (15 mg) in the form of infusion. Patients will not know about the randomization method and the considered treatment protocol. Pain intensity is measured during the first 6 hours of recovery and the first 12 hours after the operation. In the group with moderate and severe pain, 10 and 20 mg of pethidine is injected, and the consumption of the two groups is compared.</i_keyword>
      <i_keyword>intervention group: In this double-blind randomized clinical trial study, patients undergoing elective abdominal surgery with general anesthesia who are in anesthesia class 1 and 2 were interviewed before surgery and background information including gender, age, clinical and medication records were obtained from them. The question is recorded in the study checklist. After complete preparation, placement of intravenous line, monitoring and receiving oxygen for 3 to 5 minutes with premedication of midazolam 2 mg and fentanyl 2 cc and sodium thiopental 5 mg/kg and atracurium 0.5 mg/kg under anesthesia induction. They are placed and then anesthesia is administered with N2O gas and isoflurane oxygen and repetition of fentanyl and atracurium.At the end of the operation and randomly using a random table of numbers, the patients are evaluated in two groups. The second group receives only Ketorolak ampoules.Patients will not know about the randomization method and the considered treatment protocol. Pain intensity is measured during the first 6 hours of recovery and the first 12 hours after the operation. In the group with moderate and severe pain, 10 and 20 mg of pethidine is injected, and the consumption of the two groups is compared.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Type of medicine, pain intensity, sex, age, type of surgery. Timepoint: Recovery, the first 6 hours and the first 12 hours after the operation. Method of measurement: Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Islamic Azad University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-12-31</approval_date>
        <contact_name>Ethics Committee of Tehran Islamic Azad University of Medical Sciences</contact_name>
        <contact_address>No1, East Payambar Ave, Abazar Blvd, Tehran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
